A recent article, “How Rare Cannabinoids Will Impact Investing,” published in Cannabis Industry Journal, gracefully uncovered the hidden truths about rare cannabinoids, their importance, and their impact on cannabis investors. Two important human pillars of Biomedican: Maxim Mikheev and Dennis O’Neill, cleared the confusion of cannabis market investors about selecting rare cannabinoids.
After a significant increase in demand for all cannabinoid products, the race has started in the market for rare cannabinoids. The future of cannabis investing lies in the hands of rare cannabinoids investors. A report expected that the biosynthesis of rare cannabinoids would be a $25 billion market by 2025 and $40 billion by 2040.
The future of the rare cannabinoids market is solely dependent on biosynthetic cannabinoid companies. The demand for rare cannabinoids has significantly increased in pharmaceutical, CPG, nutraceuticals, cosmetics, and pet care markets. Only biosynthetic cannabinoid companies such as BioMedican can revolutionize the future of rare cannabinoids with the highest quality and lowest price rare cannabinoids.
Importance of rare cannabinoids:
As the name indicates, rare cannabinoids such as CBG, CBN, THCV, THCA, and others are present in a very minute quantity in plants. The cannabis plant can’t produce the same rare cannabinoids in its next grow and harvest cycle. Biosynthesis is an advanced production process for these rare cannabinoids, creating pharmaceutical grade, non-GMO, bioidentical, synthetic cannabinoids with a 0.0% THC at 70-90% less cost.
Research has uncovered several medical, nutraceuticals, and pharmacological benefits of rare cannabinoids. The rare cannabinoids bind different cannabinoid receptors that regulate several physiological systems of the body. These cannabinoids also help with pathological conditions such as pediatric epilepsies, glaucoma, neuropathic pain, schizophrenia, and chemotherapy-induced nausea. Various other prominent sectors such as veterinary, food, hygiene, and cosmetic industries are also interested in rare cannabinoid products.
Investing in rare cannabinoids:
The unique qualities of rare cannabinoids resulted in increased demand that asks for increased investments. The enormous beneficial potential of rare cannabinoids creates a massive global opportunity for all companies that makes rare cannabinoids products. However, biosynthetic companies will lead the market with their highest quality, highest yields, and lowest-cost cannabinoids.
Maxim Mikheev and Dennis O’Neill explained that THCV should be a priority rare cannabinoid for investors. BioMedican can now produce THCV through biosynthesis, creating a pharmaceutical-grade, organic, bioidentical compound at 70-90% less than wholesale prices. We invite our investors to make hay while the sun shines by investing in BioMedican’s produced rare cannabinoids.